The University of Southampton
University of Southampton Institutional Repository

Targeted next-generation sequencing of plasma DNA from cancer patients: factors influencing consistency with tumour DNA and prospective investigation of its utility for diagnosis

Targeted next-generation sequencing of plasma DNA from cancer patients: factors influencing consistency with tumour DNA and prospective investigation of its utility for diagnosis
Targeted next-generation sequencing of plasma DNA from cancer patients: factors influencing consistency with tumour DNA and prospective investigation of its utility for diagnosis
Use of circulating tumour DNA (ctDNA) as a liquid biopsy has been proposed for potential identification and monitoring of solid tumours. We investigate a next-generation sequencing approach for mutation detection in ctDNA in two related studies using a targeted panel. The first study was retrospective, using blood samples taken from melanoma patients at diverse timepoints before or after treatment, aiming to evaluate correlation between mutations identified in biopsy and ctDNA, and to acquire a first impression of influencing factors. We found good concordance between ctDNA and tumour mutations of melanoma patients when blood samples were collected within one year of biopsy or before treatment. In contrast, when ctDNA was sequenced after targeted treatment in melanoma, mutations were no longer found in 9 out of 10 patients, suggesting the method might be useful for detecting treatment response. Building on these findings, we focused the second study on ctDNA obtained before biopsy in lung patients, i.e. when a tentative diagnosis of lung cancer had been made, but no treatment had started. The main objective of this prospective study was to evaluate use of ctDNA in diagnosis, investigating the concordance of biopsy and ctDNA-derived mutation detection. Here we also found positive correlation between diagnostic lung biopsy results and pre-biopsy ctDNA sequencing, providing support for using ctDNA as a cost-effective, non-invasive solution when the tumour is inaccessible or when biopsy poses significant risk to the patient.
1932-6203
PJ, Kaisaki
e85cba0e-e745-4fc2-9a17-5b9c1903b74d
A, Cutts
785ad58d-d6e9-402d-892c-d4921a757c7c
N, Popitsch
de259c81-339a-410b-a02c-cd02395795cd
Karydis, Ioannis
95a2388c-7165-40e1-8b73-87234caea36d
DC, Talbot
24e073b2-38ce-4b33-8329-d8b93ff1c68e
Schuh, Anna
fab77ad0-7ddd-48d4-bfc5-5db3d3a1c299
JC, Taylor
7a9b1529-99dc-44f0-845c-139f0dca0849
PJ, Kaisaki
e85cba0e-e745-4fc2-9a17-5b9c1903b74d
A, Cutts
785ad58d-d6e9-402d-892c-d4921a757c7c
N, Popitsch
de259c81-339a-410b-a02c-cd02395795cd
Karydis, Ioannis
95a2388c-7165-40e1-8b73-87234caea36d
DC, Talbot
24e073b2-38ce-4b33-8329-d8b93ff1c68e
Schuh, Anna
fab77ad0-7ddd-48d4-bfc5-5db3d3a1c299
JC, Taylor
7a9b1529-99dc-44f0-845c-139f0dca0849

PJ, Kaisaki, A, Cutts, N, Popitsch, Karydis, Ioannis, DC, Talbot, Schuh, Anna and JC, Taylor (2016) Targeted next-generation sequencing of plasma DNA from cancer patients: factors influencing consistency with tumour DNA and prospective investigation of its utility for diagnosis. PLoS ONE. (doi:10.1371/journal.pone.0162809).

Record type: Article

Abstract

Use of circulating tumour DNA (ctDNA) as a liquid biopsy has been proposed for potential identification and monitoring of solid tumours. We investigate a next-generation sequencing approach for mutation detection in ctDNA in two related studies using a targeted panel. The first study was retrospective, using blood samples taken from melanoma patients at diverse timepoints before or after treatment, aiming to evaluate correlation between mutations identified in biopsy and ctDNA, and to acquire a first impression of influencing factors. We found good concordance between ctDNA and tumour mutations of melanoma patients when blood samples were collected within one year of biopsy or before treatment. In contrast, when ctDNA was sequenced after targeted treatment in melanoma, mutations were no longer found in 9 out of 10 patients, suggesting the method might be useful for detecting treatment response. Building on these findings, we focused the second study on ctDNA obtained before biopsy in lung patients, i.e. when a tentative diagnosis of lung cancer had been made, but no treatment had started. The main objective of this prospective study was to evaluate use of ctDNA in diagnosis, investigating the concordance of biopsy and ctDNA-derived mutation detection. Here we also found positive correlation between diagnostic lung biopsy results and pre-biopsy ctDNA sequencing, providing support for using ctDNA as a cost-effective, non-invasive solution when the tumour is inaccessible or when biopsy poses significant risk to the patient.

This record has no associated files available for download.

More information

Accepted/In Press date: 29 August 2016
e-pub ahead of print date: 14 September 2016
Published date: 14 September 2016

Identifiers

Local EPrints ID: 416172
URI: http://eprints.soton.ac.uk/id/eprint/416172
ISSN: 1932-6203
PURE UUID: c20b5e30-a2c7-4468-9d94-d910d10d38aa

Catalogue record

Date deposited: 06 Dec 2017 17:30
Last modified: 15 Mar 2024 17:09

Export record

Altmetrics

Contributors

Author: Kaisaki PJ
Author: Cutts A
Author: Popitsch N
Author: Ioannis Karydis
Author: Talbot DC
Author: Anna Schuh
Author: Taylor JC

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×